NASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis $6.16 +0.20 (+3.36%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$6.22 +0.06 (+1.06%) As of 08/18/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Verrica Pharmaceuticals Stock (NASDAQ:VRCA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VRCA alerts:Sign Up Key Stats Today's Range$5.90▼$6.3650-Day Range$5.23▼$8.7352-Week Range$3.82▼$30.90Volume40,121 shsAverage Volume54,269 shsMarket Capitalization$58.21 millionP/E RatioN/ADividend YieldN/APrice Target$80.00Consensus RatingHold Company Overview Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. Read More Verrica Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreVRCA MarketRank™: Verrica Pharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 112th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageVerrica Pharmaceuticals has received no research coverage in the past 90 days.Read more about Verrica Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.46) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Verrica Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.99% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently decreased by 32.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted2.99% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently decreased by 32.28%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.70 News SentimentVerrica Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders54.00% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verrica Pharmaceuticals' insider trading history. Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VRCA Stock News HeadlinesVerrica Posts Profit in Fiscal Q2August 14, 2025 | theglobeandmail.comVerrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 13, 2025 | finance.yahoo.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks. | American Alternative (Ad)Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | finanznachrichten.deVerrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comVerrica Pharmaceuticals Regains Nasdaq ComplianceAugust 12, 2025 | msn.comVerrica Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | globenewswire.comSee More Headlines VRCA Stock Analysis - Frequently Asked Questions How have VRCA shares performed this year? Verrica Pharmaceuticals' stock was trading at $7.00 at the beginning of 2025. Since then, VRCA stock has decreased by 12.0% and is now trading at $6.16. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its quarterly earnings data on Tuesday, August, 12th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.72. The company earned $12.70 million during the quarter, compared to analyst estimates of $4.37 million. Read the conference call transcript. When did Verrica Pharmaceuticals' stock split? Verrica Pharmaceuticals shares reverse split on Friday, July 25th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO. Who are Verrica Pharmaceuticals' major shareholders? Verrica Pharmaceuticals' top institutional shareholders include Armistice Capital LLC (96.01%), Sovran Advisors LLC (0.81%), Geode Capital Management LLC (6.99%) and Y Intercept Hong Kong Ltd (2.02%). Insiders that own company stock include Paul B Manning, Perceptive Advisors Llc, Ted White, Christopher G Hayes and Joe Bonaccorso. View institutional ownership trends. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Marathon Oil (MRO), Centrus Energy (LEU) and Clean Energy Fuels (CLNE). Company Calendar Last Earnings8/12/2025Today8/19/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRCA CIK1660334 Webwww.verrica.com Phone(434) 453-3300FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Verrica Pharmaceuticals$80.00 High Price Target$120.00 Low Price Target$20.00 Potential Upside/Downside+1,198.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($8.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$76.58 million Net MarginsN/A Pretax Margin-330.52% Return on EquityN/A Return on Assets-115.48% Debt Debt-to-Equity RatioN/A Current Ratio1.26 Quick Ratio1.17 Sales & Book Value Annual Sales$7.57 million Price / Sales7.69 Cash FlowN/A Price / Cash FlowN/A Book Value($1.07) per share Price / Book-5.76Miscellaneous Outstanding Shares9,450,000Free Float4,345,000Market Cap$58.21 million OptionableOptionable Beta1.92 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:VRCA) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access